MaxCyte, Inc. Proceeds from Notes Payable
MaxCyte, Inc. (MXCT) reported Proceeds from Notes Payable of $1.44 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-22.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2022-03-22
- MaxCyte, Inc. proceeds from notes payable for the quarter ending 2020-12-31 was $0.00.
- MaxCyte, Inc. proceeds from notes payable for the quarter ending 2020-09-30 was $0.00.
- MaxCyte, Inc. proceeds from notes payable for fiscal 2020 was $1.44M, a 70.93% decline from fiscal 2019.
- MaxCyte, Inc. proceeds from notes payable for fiscal 2019 was $4.95M.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $0.00 derived: sum of 2 quarters · filed 2022-03-22 | $1.44M 10-K · filed 2022-03-22 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.44M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $1.44M 10-Q · filed 2021-09-13 | |||
| 2019-12-31 | $4.95M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |